Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist: Spantide II

Pharmaceutical Research

Volumn 21, Issue 1, 2004, Pages 108-113

  Jayachandra Babu, R ^a   Kikwai, Loice ^a   Jaiani, Lasha T ^b   Kanikkannan, Narayanasamy ^a   Armstrong, Cheryl A ^b   Ansel, John C ^b   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cysteine HCL; Dermatitis; Skin permeation; Spantide II

Indexed keywords

ANTIINFLAMMATORY AGENT; CYSTEINE; PENETRATION ENHANCING AGENT; SPANTIDE; SPANTIDE 2; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RAT; SKIN ABSORPTION; SKIN ALLERGY;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DERMATITIS, ALLERGIC CONTACT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, INBRED C57BL; RATS; RECEPTORS, NEUROKININ-1; SKIN ABSORPTION; SUBSTANCE P; TISSUE DISTRIBUTION;

EID: 1642498299     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000012157.80716.73     Document Type: Article

References (34)

1. K. Seiert and R. D. Granstein. Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. Methods 28:97-103 (2002).
2. J. C. Ansel, A. H. Kaynard, C A. Armstrong, J. E Olerud, N. W. Bunnett, and D. G. Payan. Skin-nervous system interactions. J. Invest. Dermatol. 106:198-204 (1996).
3. J. E. Parrillo and A. S. Fauci. Mechanisms of glucocorticoid action on immune processes. Annu. Rev. Pharmacol. Toxicol. 19: 179-201 (1979).
4. A. N. Anigbogu and H. I. Maibach. Topical corticosteroid therapy. In L. Millikan (ed.), Drug Therapy in Dermatology, Basic and Clinical Dermatology. Marcel Dekker, New York, 2000, pp. 1-29.
5. T. E. Scholzen, T. Brzoska, D. H. Kalden, F. O'Reilly, C. A. Armstrong, T. A. Luger, and J. C. Ansel. Effect of ultraviolet light on the release of neuropeptides and neuroendocrine hormones in the skin: mediators of photodermatitis and cutaneous inflammation. J. Invest. Dermatol. Symp. Proc 4:55-60 (1999).
6. J. R. Brown, P. Perry, S. Hefeneider, and A. C. Ansel. Neuropeptide modulation of keratinocyte cytokine production. In P. Oppenheim and D. Kluger (eds.), Molecular and Cellular Biology of Cytokines. Wiley-Liss, New York, 1990, pp. 451-456
7. T. Andoh, T. Nagasawa, M. Satoh, and Y. Kuraishi. Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J. Pharmacol. Exp. Ther. 286: 1140-1145 (1998).
8. H. Inoue, N. Nagata, and Y. Koshihara. Involvement of substance P as a mediator in capsaicin-induced mouse ear edema. Inflamm. Res. 44(11):470-474 (1995).
9. X. J. Xu, J. X. Hao, Z. Wiesenfeld-Hallin, R. Hakanson, K. Folkers, and T. Hokfelt. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic c-fiber stimulation in rat hindpaw. Neuroscience 42:731-737 (1991).
10. R. B. Meyer, W. Kreis, J. Eschbach, V. O'Mara, S. Rosen, and D. Sibalis. Successful transdermal administration of therapeutic doses of a polypeptide to normal human volunteers. Clin. Pharmacol. Ther. 44:607-612 (1988).
11. A. Ruland, J. Kreuter, and J. H. Rytting. Transdermal delivery of tetrapeptide hisetal (melanotropin (6-9). I. Effect of various penetration enhancers: In vitro study across hairless mouse skin. Int. J. Pharm. 101:57-61 (1974).
12. S. E. Cross and M. S. Roberts. Targeting local tissues by transdermal application: understanding drug physicochemical properties that best exploit protein binding and blood flow effects. Drug Dev. Res. 46:309-315 (1999).
13. B. M. Magnusson and P. Runn. Effect of penetration enhancers on the permeation of the thyrotropin releasing hormone analogue pGlu-3-methyl-His-Pro amide through human epidermis. Int. J. Pharm. 178:149-159 (1999).
14. B. M Magnusson, L. O. Koskinen, M. Koch, and K. Karlsson. Biological effects after percutaneous absorption of thyrotropin-releasing hormone and its analogue M-TRH. Peptides 22:73-79 (2001).
15. R. J. Babu, N. Kanikkannan, L. Kikwai, and M. Singh. Evaluation of sulfhydryl compounds as novel skin penetration enhancers. AAPS Pharm. Sci. 4(4):Abstract R6079 (2002). Available from http://www.aapspharmsci.org.
16. Z. Y. Wang, D. M. Feng, Y. L. Wang, S. R. Tung, K. Wong, G. R. Strichartz, K. Folkers, and R. Hakanson. Pharmacological assessment of spantide II analogues. Eur. J. Pharmacol. 260:121-128 (1994).
17. Y. Wang, C. Hong, W. Chiu, and J. Fang. In vitro and in vivo evaluations of topically applied capsaicin and nonivamide from hydrogels. Int. J. Pharm. 224:89-104 (2001).
18. C. Surber, F. P. Schwarb, and E. W. Smith. Tape stripping technique. In R. L. Bronaugh and H. I. Maibach (eds.), Percutaneous Absorption, Drugs - Cosmetics - Mechanisms - Methodology, Marcel Dekker, New York, 1999, pp. 395-409.
19. S. Grabbe, R. S. Bhardwaj, K. Mahnke, M. M. Simon, T. Schwarz, and T. A. Luger. Alpha-melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J. Immunol. 156:473-478 (1996).
20. R. J. Scheuplein and I. H. Blank. Permeability of the skin. Physiol. Rev. 51:702-747 (1971).
21. G. G. Hillebrand and V. Gartstein. Depilatory compositions. U.S. Patent No. US5897857, April 27, 1999.
22. C. Weber, M. Podda, M. Rallis, J. J. Thiele, M. G. Traber, and L. Packer. Efficacy of topically applied tocopherols and tocotrienols in protection of murine skin from oxidative damage induced by UV-irradiation. Free Radic. Biol. Med. 22:761-769 (1997).
23. R. D. Ley and V. E. Reeve. Chemoprevention of ultraviolet radiation induced skin cancer. Environ. Health Perspect. 105:981-984 (1997).
24. B. A. Jurkiewicz, D. L. Bissett, and G. R. Buettner. Effect of topically applied tocopherol on ultraviolet radiation-mediated free radical damage in skin. J. Invest. Dermatol. 104:484-488 (1995).
25. L. L. Hruza and A. P. Pentland. Mechanisms of UV-induced inflammation. J. Invest. Dermatol. 100:35S-41S (1993).
26. N. Kanikkannan and M. Singh. Evaluation of sulfhydryl compounds as novel skin penetration enhancers. AAPS Pharm. Sci. 3 (3): Abstract (2001). Available from http://www.aapspharmsci.org.
27. P. Anand, D. R. Springall, M. A. Blank, D. Sellu, J. M. Ploak, and S. R. Bloom. Neuropeptides in skin disease: increased VIP in eczema and psoriasis but not axillary hyperhydrisis. Br. J. Dermatol. 124:547-549 (1991).
28. C. Pincelli, F. Fantini, P. Romualdi, G. Lesa, and A. Giannetti. Skin levels of vasoactive intestinal peptidein atopic dermatitis. Arch. Dermatol. Res. 283:230-232 (1991).
29. W. R. Pfister and D. S. Hsieh. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations. Med. Device Technol. 1:48-55 (1990).
30. R. O. Potts. Physical characterization of stratum corneum: the relationship of mechanical and barrier properties to lipid and protein structure. In J. Hadgraft and R. H. Guy (eds.), Transdermal Drug Delivery: Developmental Issues and Research Initiatives. Marcel Dekker, New York, 1989, pp. 23-57.
31. T. E. Scholzen, M. Steinhoff, P. Bonaccorsi, R. Klein, S. Amadesi, P. Geppetti, B. Lu, N. P. Gerard, J. E. Olerud, T. A. Luger, N. W. Bunnett, E. F. Grady, C. A. Armstrong, and J. C. Ansel. Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis. J. Immunol. 166:1285-1291 (2001).
32. S. D. Brain. Sensory neuropeptides: their role in inflammation and wound healing. Immunopharmacology 37:133-152 (1997).
33. T. E. Scholzen, C. A. Armstrong, N. W. Bunnett, T. A. Luger, J. E. Olerud, and J. C Ansel. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp. Dermatol. 7:81-96 (1998).
34. B. W. Barry. Reflections on transdermal drug delivery. Pharm. Sci. Technol. Today 2:41-43 (1999).